These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22906540)

  • 1. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.
    Wu X; Smavadati S; Nordfjäll K; Karlsson K; Qvarnström F; Simonsson M; Bergqvist M; Gryaznov S; Ekman S; Paulsson-Karlsson Y
    Biochim Biophys Acta; 2012 Dec; 1823(12):2130-5. PubMed ID: 22906540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma.
    Wu X; Zhang J; Yang S; Kuang Z; Tan G; Yang G; Wei Q; Guo Z
    Oncotarget; 2017 Feb; 8(8):13600-13619. PubMed ID: 28099140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
    Hu Y; Bobb D; Lu Y; He J; Dome JS
    Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
    Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
    Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.
    Hu Y; Bobb D; He J; Hill DA; Dome JS
    Cancer Biol Ther; 2015; 16(6):949-57. PubMed ID: 25920748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
    Koziel JE; Herbert BS
    Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.
    Joseph I; Tressler R; Bassett E; Harley C; Buseman CM; Pattamatta P; Wright WE; Shay JW; Go NF
    Cancer Res; 2010 Nov; 70(22):9494-504. PubMed ID: 21062983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomere length, telomerase activity and telomerase RNA expression in human esophageal cancer cells: correlation with cell proliferation, differentiation and chemosensitivity to anticancer drugs.
    Asai A; Kiyozuka Y; Yoshida R; Fujii T; Hioki K; Tsubura A
    Anticancer Res; 1998; 18(3A):1465-72. PubMed ID: 9673357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term treatment with imetelstat sensitizes hematopoietic malignant cells to a genotoxic agent via suppression of the telomerase-mediated DNA repair process.
    Hidaka D; Onozawa M; Miyashita N; Yokoyama S; Nakagawa M; Hashimoto D; Teshima T
    Leuk Lymphoma; 2020 Nov; 61(11):2722-2732. PubMed ID: 32571117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis.
    Mosoyan G; Kraus T; Ye F; Eng K; Crispino JD; Hoffman R; Iancu-Rubin C
    Leukemia; 2017 Nov; 31(11):2458-2467. PubMed ID: 28270692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.
    Barszczyk M; Buczkowicz P; Castelo-Branco P; Mack SC; Ramaswamy V; Mangerel J; Agnihotri S; Remke M; Golbourn B; Pajovic S; Elizabeth C; Yu M; Luu B; Morrison A; Adamski J; Nethery-Brokx K; Li XN; Van Meter T; Dirks PB; Rutka JT; Taylor MD; Tabori U; Hawkins C
    Acta Neuropathol; 2014 Dec; 128(6):863-77. PubMed ID: 25120190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
    Tefferi A; Lasho TL; Begna KH; Patnaik MM; Zblewski DL; Finke CM; Laborde RR; Wassie E; Schimek L; Hanson CA; Gangat N; Wang X; Pardanani A
    N Engl J Med; 2015 Sep; 373(10):908-19. PubMed ID: 26332545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.
    Marian CO; Cho SK; McEllin BM; Maher EA; Hatanpaa KJ; Madden CJ; Mickey BE; Wright WE; Shay JW; Bachoo RM
    Clin Cancer Res; 2010 Jan; 16(1):154-63. PubMed ID: 20048334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.
    Salloum R; Hummel TR; Kumar SS; Dorris K; Li S; Lin T; Daryani VM; Stewart CF; Miles L; Poussaint TY; Stevenson C; Goldman S; Dhall G; Packer R; Fisher P; Pollack IF; Fouladi M; Boyett J; Drissi R
    J Neurooncol; 2016 Sep; 129(3):443-451. PubMed ID: 27350411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imetelstat (a telomerase antagonist) exerts off‑target effects on the cytoskeleton.
    Mender I; Senturk S; Ozgunes N; Akcali KC; Kletsas D; Gryaznov S; Can A; Shay JW; Dikmen ZG
    Int J Oncol; 2013 May; 42(5):1709-15. PubMed ID: 23545855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of Gleditsia sinensis fruit extract on telomerase activity and oncogenic expression in human esophageal squamous cell carcinoma.
    Tang WK; Chui CH; Fatima S; Kok SH; Pak KC; Ou TM; Hui KS; Wong MM; Wong J; Law S; Tsao SW; Lam KY; Beh PS; Srivastava G; Ho KP; Chan AS; Tang JC
    Int J Mol Med; 2007 Jun; 19(6):953-60. PubMed ID: 17487429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential transcriptional regulation of human telomerase in a cellular model representing important genetic alterations in esophageal squamous carcinogenesis.
    Quante M; Heeg S; von Werder A; Goessel G; Fulda C; Doebele M; Nakagawa H; Beijersbergen R; Blum HE; Opitz OG
    Carcinogenesis; 2005 Nov; 26(11):1879-89. PubMed ID: 15958520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of telomerase inhibition on prostate tumor-initiating cells.
    Marian CO; Wright WE; Shay JW
    Int J Cancer; 2010 Jul; 127(2):321-31. PubMed ID: 19908230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of valproic acid in DNA double-strand break repair after irradiation in esophageal squamous carcinoma cells.
    Makita N; Ninomiya I; Tsukada T; Okamoto K; Harada S; Nakanuma S; Sakai S; Makino I; Kinoshita J; Hayashi H; Oyama K; Nakagawara H; Miyashita T; Tajima H; Takamura H; Fushida S; Ohta T
    Oncol Rep; 2015 Sep; 34(3):1185-92. PubMed ID: 26135807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and mechanism of PinX1 and telomerase activity in the carcinogenesis of esophageal epithelial cells.
    Zuo J; Wang DH; Zhang YJ; Liu L; Liu FL; Liu W
    Oncol Rep; 2013 Oct; 30(4):1823-31. PubMed ID: 23912465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.